FLNB and renal cell adenocarcinoma: With a similar approach, submodels built from human genome-scale models have been used to generate several testable hypotheses, e.g., to compare wild-type and Fh1-deficient kidney mouse cells, and to predict further gene knockouts that affect growth in the Fh1-deficient cells but do not affect the wild-type cells, therefore suggesting targets for treating hereditary leiomyomatosis and renal-cell cancer [153].